688117 圣诺生物
已收盘 09-11 15:00:01
资讯
新帖
简况
每周股票复盘：圣诺生物（688117）高管增持计划过半未实施
证券之星 · 09-13 02:42
每周股票复盘：圣诺生物（688117）高管增持计划过半未实施
股市必读：圣诺生物新发布《关于高级管理人员增持公司股份进展的公告》
证券之星 · 09-09
股市必读：圣诺生物新发布《关于高级管理人员增持公司股份进展的公告》
每周股票复盘：圣诺生物（688117）利那洛肽胶囊获注册证
证券之星 · 09-06
每周股票复盘：圣诺生物（688117）利那洛肽胶囊获注册证
股市必读：圣诺生物新发布《关于自愿披露利那洛肽胶囊获得药品注册证书的公告》
证券之星 · 09-04
股市必读：圣诺生物新发布《关于自愿披露利那洛肽胶囊获得药品注册证书的公告》
圣诺生物最新公告：醋酸特利加压素原料药获上市批准
证券之星 · 08-28
圣诺生物最新公告：醋酸特利加压素原料药获上市批准
每周股票复盘：圣诺生物（688117）Q2收入增71.62%，股东户数增14.2%
证券之星 · 08-23
每周股票复盘：圣诺生物（688117）Q2收入增71.62%，股东户数增14.2%
图解圣诺生物中报：第二季度单季净利润同比增长64.52%
证券之星 · 08-20
图解圣诺生物中报：第二季度单季净利润同比增长64.52%
圣诺生物（688117）披露2026年半年度报告，8月19日股价下跌1.65%
证券之星 · 08-19
圣诺生物（688117）披露2026年半年度报告，8月19日股价下跌1.65%
股市必读：圣诺生物新发布《关于召开2026年半年度业绩说明会的公告》
证券之星 · 08-18
股市必读：圣诺生物新发布《关于召开2026年半年度业绩说明会的公告》
圣诺生物（688117）披露2026年限制性股票激励计划首次授予公告，7月23日股价下跌2.67%
证券之星 · 07-23
圣诺生物（688117）披露2026年限制性股票激励计划首次授予公告，7月23日股价下跌2.67%
7月21日圣诺生物发布公告，股东增持200.55万股
证券之星 · 07-21
7月21日圣诺生物发布公告，股东增持200.55万股
每周股票复盘：圣诺生物（688117）上半年净利预增43.23%至64.79%
证券之星 · 07-19
每周股票复盘：圣诺生物（688117）上半年净利预增43.23%至64.79%
圣诺生物（688117）披露2026年限制性股票激励计划首次授予激励对象名单审核及公示情况说明，7月17日股价下跌14.29%
证券之星 · 07-17
圣诺生物（688117）披露2026年限制性股票激励计划首次授予激励对象名单审核及公示情况说明，7月17日股价下跌14.29%
股市必读：圣诺生物（688117）新发布《关于2025年年度报告的信息披露监管问询函的回复公告》
证券之星 · 07-13
股市必读：圣诺生物（688117）新发布《关于2025年年度报告的信息披露监管问询函的回复公告》
今晚，七家公司发布利好！
证券之星 · 07-12
今晚，七家公司发布利好！
圣诺生物：预计2026年1-6月归属净利润盈利1.27亿元至1.47亿元
证券之星 · 07-12
圣诺生物：预计2026年1-6月归属净利润盈利1.27亿元至1.47亿元
圣诺生物最新公告：预计2026年半年度净利润同比增长43.23%-64.79%
证券之星 · 07-12
圣诺生物最新公告：预计2026年半年度净利润同比增长43.23%-64.79%
圣诺生物：预计2026年上半年净利同比增43.23%-64.79%
格隆汇 · 07-12
圣诺生物：预计2026年上半年净利同比增43.23%-64.79%
圣诺生物（688117）披露2025年年度报告监管问询函回复公告，7月10日股价上涨2.74%
证券之星 · 07-10
圣诺生物（688117）披露2025年年度报告监管问询函回复公告，7月10日股价上涨2.74%
圣诺生物(688117.SH)拟推2026年限制性股票激励计划
智通财经 · 07-07
圣诺生物(688117.SH)拟推2026年限制性股票激励计划
加载更多
公司概况
公司名称：
成都圣诺生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-06-03
主营业务：
成都圣诺生物科技股份有限公司的主营业务是为国内外医药企业的多肽类创新药研发提供药学研究和定制生产服务，自主研发、生产和销售多肽类仿制药原料药和制剂产品以及多肽药物生产技术转让服务。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。公司在报告期内荣获“2026中国医药CDMO企业20强”。
发行价格：
17.90
{"stockData":{"symbol":"688117","market":"SH","secType":"STK","nameCN":"圣诺生物","latestPrice":22.37,"timestamp":1789110001000,"preClose":22.8,"halted":0,"volume":3915723,"delay":0,"changeRate":-0.0189,"floatShares":220000000,"shares":220000000,"eps":0.9266,"marketStatus":"已收盘","change":-0.43,"latestTime":"09-11 15:00:01","open":22.51,"high":22.85,"low":22.18,"amount":87602100,"amplitude":0.0294,"askPrice":22.38,"askSize":499,"bidPrice":22.37,"bidSize":45,"shortable":0,"etf":0,"ttmEps":0.9266,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.8,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":25.08,"lowLimit":20.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":220340369,"isCdr":false,"pbRate":4.31,"roa":"--","peRate":24.142025,"roe":"12.1%","epsLYR":1,"committee":-0.424084,"marketValue":4929000000,"turnoverRate":0.0178,"status":1,"afterMarket":{"amount":0,"volume":0,"close":22.37,"buyVolume":0,"sellVolume":0,"time":1789112037746,"indexStatus":"已收盘 09-11 15:30:00","preClose":22.8},"floatMarketCap":4929000000},"requestUrl":"/m/hq/s/688117","defaultTab":"news","newsList":[{"id":"2667350779","title":"每周股票复盘：圣诺生物（688117）高管增持计划过半未实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2667350779","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667350779?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:42","pubTimestamp":1789238533,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，圣诺生物报收于22.37元，较上周的23.59元下跌5.17%。本周，圣诺生物9月8日盘中最高价报23.89元。截至2026年9月9日，增持计划实施期限已过半，饶进先生尚未增持公司股份，累计增持金额为0元。本次增持计划可能因资本市场变化等因素存在无法实施的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666905372","title":"股市必读：圣诺生物新发布《关于高级管理人员增持公司股份进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666905372","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666905372?lang=zh_cn&edition=full","pubTime":"2026-09-09 02:56","pubTimestamp":1788893773,"startTime":"0","endTime":"0","summary":"公司公告汇总关于高级管理人员增持公司股份进展的公告成都圣诺生物科技股份有限公司副总经理、董事会秘书饶进先生计划自2026年6月9日起6个月内增持公司股份，金额不低于800万元且不超过1000万元。截至2026年9月9日，增持计划实施期限已过半，饶进先生尚未增持公司股份，累计增持金额为0元。饶进先生对公司发展前景保持信心，认可长期投资价值，后续将继续按计划实施增持。本次增持计划可能因资本市场变化等因素存在无法实施的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936668","title":"每周股票复盘：圣诺生物（688117）利那洛肽胶囊获注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665936668?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:28","pubTimestamp":1788636491,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，圣诺生物报收于23.59元，较上周的23.93元下跌1.42%。本周，圣诺生物9月4日盘中最高价报24.34元。8月31日盘中最低价报23.35元。圣诺生物当前最新总市值51.98亿元，在化学制药板块市值排名88/149，在两市A股市值排名3097/5214。公司利那洛肽原料药已完成美国FDA DMF备案。此次获批有助于丰富公司产品管线，提升在消化道领域的市场竞争力。具体销售情况受国家政策、市场环境等因素影响，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664057208","title":"股市必读：圣诺生物新发布《关于自愿披露利那洛肽胶囊获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664057208","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664057208?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:29","pubTimestamp":1788456551,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，圣诺生物报收于23.86元，上涨0.25%，换手率2.02%，成交量4.46万手，成交额1.06亿元。公司公告汇总关于自愿披露利那洛肽胶囊获得药品注册证书的公告成都圣诺生物科技股份有限公司全资子公司成都圣诺生物制药有限公司近日收到国家药品监督管理局签发的利那洛肽胶囊《药品注册证书》，药品注册标准编号为YBH25592026，规格为290μg，注册分类为化学药品4类。公司利那洛肽原料药已完成美国FDA DMF备案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662535067","title":"圣诺生物最新公告：醋酸特利加压素原料药获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2662535067","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662535067?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:24","pubTimestamp":1787916281,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)公告称，公司全资子公司成都圣诺生物制药有限公司近日收到国家药监局签发的醋酸特利加压素原料药《化学原料药上市申请批准通知书》。该药品主要用于收缩血管和抗出血，适用于胃肠道和泌尿生殖系统出血。此次获批将进一步丰富公司原料药产品线，优化产业布局，但具体销售情况受政策及市场环境影响，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800045232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211630","title":"每周股票复盘：圣诺生物（688117）Q2收入增71.62%，股东户数增14.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211630?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:34","pubTimestamp":1787420052,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，圣诺生物报收于25.79元，较上周的27.03元下跌4.59%。本周，圣诺生物8月19日盘中最高价报28.37元。股本股东变化股东户数变动截至2026年6月30日，圣诺生物股东户数为1.14万户，较3月31日增加1422.0户，增幅14.2%。业绩披露要点财务报告2026年上半年，圣诺生物主营收入5.07亿元，同比上升50.27%；归母净利润1.35亿元，同比上升51.98%；扣非净利润1.34亿元，同比上升50.19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660380427","title":"图解圣诺生物中报：第二季度单季净利润同比增长64.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660380427","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660380427?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:25","pubTimestamp":1787160317,"startTime":"0","endTime":"0","summary":"证券之星消息，圣诺生物2026年中报显示，上半年度公司主营收入5.07亿元，同比上升50.27%；归母净利润1.35亿元，同比上升51.98%；扣非净利润1.34亿元，同比上升50.19%；其中2026年第二季度，公司单季度主营收入2.63亿元，同比上升71.62%；单季度归母净利润6883.18万元，同比上升64.52%；单季度扣非净利润6850.72万元，同比上升64.95%；负债率44.8%，投资收益3.18万元，财务费用1044.68万元，毛利率58.73%。财报数据概要请见下图:本文数据来源于圣诺生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660544429","title":"圣诺生物（688117）披露2026年半年度报告，8月19日股价下跌1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660544429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660544429?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:10","pubTimestamp":1787148624,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，圣诺生物报收于26.9元，较前一交易日下跌1.65%，最新总市值为59.27亿元。该股当日开盘27.31元，最高28.37元，最低26.5元，成交额达3.97亿元，换手率为6.6%。近日，成都圣诺生物科技股份有限公司披露2026年半年度报告摘要。经营活动产生的现金流量净额为87,225,669.48元，同比增长6.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900042964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660543112","title":"股市必读：圣诺生物新发布《关于召开2026年半年度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660543112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660543112?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:55","pubTimestamp":1786989313,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，圣诺生物报收于27.03元，上涨0.0%，换手率3.42%，成交量7.53万手，成交额2.03亿元。当日关注点交易信息汇总：8月17日主力资金净流出175.16万元，占总成交额0.86%。公司公告汇总：圣诺生物将于2026年8月24日10:00-11:00召开2026年半年度业绩说明会，通过上证路演中心以网络文字互动方式进行。投资者可于8月18日至8月21日16:00前通过上证路演中心提问预征集栏目或公司邮箱提交问题。说明会后可通过该平台查看会议内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800002028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653872996","title":"圣诺生物（688117）披露2026年限制性股票激励计划首次授予公告，7月23日股价下跌2.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653872996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653872996?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:39","pubTimestamp":1784817555,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，圣诺生物报收于23.36元，较前一交易日下跌2.67%，最新总市值为51.47亿元。近日，成都圣诺生物科技股份有限公司披露《关于向激励对象首次授予限制性股票的公告》。公司于2026年7月23日召开第五届董事会第四次会议，确定当日为2026年限制性股票激励计划的首次授予日，向113名激励对象首次授予449.00万股第二类限制性股票，授予价格为14.88元/股。本次授予已获得股东会审议通过并完成相关信息披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300048278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271997","title":"7月21日圣诺生物发布公告，股东增持200.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271997","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653271997?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:01","pubTimestamp":1784631676,"startTime":"0","endTime":"0","summary":"证券之星消息，7月21日圣诺生物发布公告《圣诺生物:关于控股股东增持股份结果暨权益变动触及1%刻度的公告》，其股东四川赛诺投资有限公司于2026年7月17日至2026年7月21日间合计增持200.55万股，占公司目前总股本的0.9102%，变动期间该股股价下跌15.15%，截止7月21日收盘报24.65元。股东增减持详情见下表：根据圣诺生物2026年一季报公布的十大股东详情如下：本文数据来源于圣诺生物公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100037880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652823749","title":"每周股票复盘：圣诺生物（688117）上半年净利预增43.23%至64.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652823749","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652823749?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:35","pubTimestamp":1784396110,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，圣诺生物报收于24.9元，较上周的29.21元下跌14.76%。本周关注点公司公告汇总：预计2026年上半年净利润同比增长43.23%至64.79%公司公告汇总：拟授予469.00万股限制性股票用于股权激励公司公告汇总：2026年限制性股票激励对象名单公示无异议公司公告汇总成都圣诺生物科技股份有限公司预计2026年半年度实现归属于母公司所有者的净利润12,741.40万元至14,659.46万元，同比增长43.23%至64.79%；扣除非经常性损益后的净利润为12,595.48万元至14,404.47万元，同比增长44.77%至60.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652328604","title":"圣诺生物（688117）披露2026年限制性股票激励计划首次授予激励对象名单审核及公示情况说明，7月17日股价下跌14.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652328604","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652328604?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:10","pubTimestamp":1784297433,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，圣诺生物报收于24.9元，较前一交易日下跌14.29%，最新总市值为54.86亿元。近日，成都圣诺生物科技股份有限公司披露《董事会薪酬与考核委员会关于公司2026年限制性股票激励计划首次授予激励对象名单的审核意见及公示情况说明》。公告显示，公司于2026年7月8日至7月17日在内部公示激励对象名单，公示期间未收到异议。董事会薪酬与考核委员会认为激励对象主体资格合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700044615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651651991","title":"股市必读：圣诺生物（688117）新发布《关于2025年年度报告的信息披露监管问询函的回复公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2651651991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651651991?lang=zh_cn&edition=full","pubTime":"2026-07-13 01:07","pubTimestamp":1783876028,"startTime":"0","endTime":"0","summary":"关于2025年年度报告的信息披露监管问询函的回复公告2025年营收7.41亿元，同比增长62.57%，主要因GLP-1原料药境外销售增加；原料药业务中司美格鲁肽、替尔泊肽销售大幅增长；制剂业务受集采影响价格下滑；前五名客户占比65.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300000578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650163295","title":"今晚，七家公司发布利好！","url":"https://stock-news.laohu8.com/highlight/detail?id=2650163295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650163295?lang=zh_cn&edition=full","pubTime":"2026-07-12 20:31","pubTimestamp":1783859460,"startTime":"0","endTime":"0","summary":"业绩变动主要系报告期内公司产品销售毛利率得到改善，从而利润增加。4，亚联机械：2026年半年度净利润同比增长60.06%亚联机械公告称，公司发布2026年半年度业绩快报，实现营业收入5.15亿元，同比增长36.93%；归属于上市公司股东的净利润1.57亿元，同比增长60.06%。业绩增长主要系2026年上半年高单价生产线项目验收较多，且整体毛利率水平较高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-12/doc-inihqett7718793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0037","BK0012","BK0155","001313","BK0010","BK0051","BK0024","BK0183","BK0014","600118","603819","600884","688117","BK0188","BK0239","BK0238","002866","BK0214","BK0059","BK0028","BK0005","BK0224","BK0251","BK0000","001395"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2650168766","title":"圣诺生物：预计2026年1-6月归属净利润盈利1.27亿元至1.47亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168766","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650168766?lang=zh_cn&edition=full","pubTime":"2026-07-12 18:00","pubTimestamp":1783850441,"startTime":"0","endTime":"0","summary":"证券之星消息，圣诺生物发布业绩预告，预计2026年1-6月归属净利润盈利1.27亿元至1.47亿元。圣诺生物2026年一季报显示，一季度公司主营收入2.44亿元，同比上升32.52%；归母净利润6636.22万元，同比上升40.84%；扣非净利润6587.3万元，同比上升37.4%；负债率44.0%，投资收益34.14万元，财务费用438.3万元，毛利率59.87%。本文数据来源于《圣诺生物:2026年半年度业绩预告的自愿性披露公告》，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200009723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650168634","title":"圣诺生物最新公告：预计2026年半年度净利润同比增长43.23%-64.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168634","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650168634?lang=zh_cn&edition=full","pubTime":"2026-07-12 16:19","pubTimestamp":1783844386,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)公告称，预计2026年半年度归属于母公司所有者的净利润为1.27亿元-1.47亿元，同比增长43.23%-64.79%。业绩变动主要系公司多肽原料药业务持续增长，新建产能逐步释放，规模化生产效应与工艺优化提升整体盈利能力。注：公司Q2净利润预计0.61亿-0.8亿，Q1净利润0.66亿，据此计算，Q2净利润预计环比变动-8%-20%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200005276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650168506","title":"圣诺生物：预计2026年上半年净利同比增43.23%-64.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168506","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650168506?lang=zh_cn&edition=full","pubTime":"2026-07-12 16:19","pubTimestamp":1783844372,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135108","title":"圣诺生物（688117）披露2025年年度报告监管问询函回复公告，7月10日股价上涨2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650135108?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:16","pubTimestamp":1783692983,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，圣诺生物报收于29.21元，较前一交易日上涨2.74%，最新总市值为64.36亿元。该股当日开盘28.2元，最高30.3元，最低27.78元，成交额达3.33亿元，换手率为5.12%。近日，圣诺生物发布《关于2025年年度报告的信息披露监管问询函的回复公告》。公告显示，公司就2025年年度报告收到上交所问询函，针对营业收入、客户集中度、应收账款、存货、产能建设、偿债能力等问题逐一回复。公司2025年营收7.41亿元，同比增长62.57%，主要因GLP-1原料药境外销售增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649813519","title":"圣诺生物(688117.SH)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2649813519","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649813519?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:33","pubTimestamp":1783420402,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺生物(688117.SH)披露2026年限制性股票激励计划(草案)，拟授予激励对象的限制性股票数量为469万股，约占激励计划草案公布日公司股本总额的2.13%。其中，首次授予限制性股票449万股，首次授予激励对象共计113人，授予价格为14.88元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789343443832,"stockEarnings":[{"period":"1week","weight":-0.0517},{"period":"1month","weight":-0.1507},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.1581},{"period":"1year","weight":-0.2365},{"period":"ytd","weight":-0.163}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都圣诺生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11436人(较上一季度增加14.20%)","perCapita":"19267股","listingDate":"2021-06-03","address":"四川省成都市大邑县大安路98号","registeredCapital":"22034万元","survey":" 成都圣诺生物科技股份有限公司的主营业务是为国内外医药企业的多肽类创新药研发提供药学研究和定制生产服务，自主研发、生产和销售多肽类仿制药原料药和制剂产品以及多肽药物生产技术转让服务。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。公司在报告期内荣获“2026中国医药CDMO企业20强”。","listedPrice":17.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣诺生物,688117,圣诺生物股票,圣诺生物股票老虎,圣诺生物股票老虎国际,圣诺生物行情,圣诺生物股票行情,圣诺生物股价,圣诺生物股市,圣诺生物股票价格,圣诺生物股票交易,圣诺生物股票购买,圣诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}